Celgene (CELG +0.7%) says that abstracts reviewing results from a phase III metastatic melanoma...
Thursday, October 25, 2012, 10:40 AM ETCelgene (CELG +0.7%) says that abstracts reviewing results from a phase III metastatic melanoma study with Abraxane for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal. Results from the study show that the drug demonstrates significant improvement in progression-free survival when compared to standard chemotherapy in advanced melanoma patients. (abstract)
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles